[go: up one dir, main page]

CL2014002975A1 - Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. - Google Patents

Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.

Info

Publication number
CL2014002975A1
CL2014002975A1 CL2014002975A CL2014002975A CL2014002975A1 CL 2014002975 A1 CL2014002975 A1 CL 2014002975A1 CL 2014002975 A CL2014002975 A CL 2014002975A CL 2014002975 A CL2014002975 A CL 2014002975A CL 2014002975 A1 CL2014002975 A1 CL 2014002975A1
Authority
CL
Chile
Prior art keywords
cells
surveillance
diagnosis
cancer
ratio
Prior art date
Application number
CL2014002975A
Other languages
English (en)
Inventor
Jirina Bartunková
Radek Spísec
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As filed Critical Sotio As
Publication of CL2014002975A1 publication Critical patent/CL2014002975A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4915Blood using flow cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514CD4
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517CD8
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CL2014002975A 2012-07-02 2014-11-03 Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. CL2014002975A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
US201261672941P 2012-07-18 2012-07-18

Publications (1)

Publication Number Publication Date
CL2014002975A1 true CL2014002975A1 (es) 2015-04-24

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002975A CL2014002975A1 (es) 2012-07-02 2014-11-03 Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.

Country Status (18)

Country Link
US (1) US20150337384A1 (es)
EP (2) EP2682750A1 (es)
JP (1) JP2015526709A (es)
KR (1) KR20150035521A (es)
CN (1) CN104364656A (es)
AU (1) AU2013286134A1 (es)
BR (1) BR112014026661A2 (es)
CA (1) CA2872668A1 (es)
CL (1) CL2014002975A1 (es)
EA (1) EA201500080A1 (es)
HK (1) HK1202618A1 (es)
IL (1) IL236197A0 (es)
IN (1) IN2015DN00678A (es)
MX (1) MX2014013079A (es)
PH (1) PH12014502436A1 (es)
SG (1) SG11201406581UA (es)
WO (1) WO2014005909A1 (es)
ZA (1) ZA201409298B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2701092T5 (es) 2014-02-24 2022-05-12 Ventana Med Syst Inc Procedimientos, kits y sistemas para puntuar la respuesta inmunitaria al cáncer por detección simultánea de CD3, CD8, CD20 y FOXP3
CN107073038A (zh) * 2014-03-14 2017-08-18 宾夕法尼亚大学理事会 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性t細胞の誘導
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
WO2018209404A1 (en) * 2017-05-19 2018-11-22 Royal Melbourne Institute Of Technology Predicting responders to cyclophosphamide therapy
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
HRP20231295T1 (hr) 2018-07-10 2024-02-02 Novartis Ag Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
CN112740042A (zh) * 2018-09-20 2021-04-30 文塔纳医疗系统公司 基于大小门控以分析流式细胞术数据

Also Published As

Publication number Publication date
MX2014013079A (es) 2014-12-08
AU2013286134A1 (en) 2015-01-22
BR112014026661A2 (pt) 2017-06-27
JP2015526709A (ja) 2015-09-10
HK1202618A1 (en) 2015-10-02
IL236197A0 (en) 2015-01-29
SG11201406581UA (en) 2015-01-29
PH12014502436A1 (en) 2015-01-12
WO2014005909A1 (en) 2014-01-09
ZA201409298B (en) 2015-12-23
IN2015DN00678A (es) 2015-06-26
KR20150035521A (ko) 2015-04-06
EP2682750A1 (en) 2014-01-08
CN104364656A (zh) 2015-02-18
EP2867677A1 (en) 2015-05-06
EA201500080A1 (ru) 2015-06-30
US20150337384A1 (en) 2015-11-26
CA2872668A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
MX2017003790A (es) Detección de secuencias diana por percepción de nanoporos de sondas sintéticas.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
IL262359A (en) Ex vivo bite-activated t cells
WO2016040775A8 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
WO2015116868A3 (en) Molecular profiling of immune modulators
MX2016013493A (es) Metodos, kits y aparato para expandir una población de células.
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
BR112015011601A2 (pt) aparelho, método, e um ou mais meios de armazenamento, não transitórios, legíveis por computador
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
WO2016063068A3 (en) Method and apparatus for the analysis of compounds
BR112015032544A2 (pt) bactéria probiótica compreendendo metais, nanopartículas de metal e usos das mesmas
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
WO2015187727A3 (en) Molecular mammography
BR112015027249A2 (pt) método de diagnóstico de câncer
AR099753A1 (es) Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
WO2016069612A3 (en) Biomarkers for early diagnosis and differentiation of mycobacterial infection
WO2015107430A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
BR112017013154A2 (pt) método para o monitoramento da evolução de um indicador usado para indicar o estado físico de um indivíduo, e dispositivo de monitoramento.
BR112014032456A2 (pt) métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento
IT201600109735A1 (it) Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla.
UY34667A (es) ?método y dispositivo para el tratamiento de trastornos del colesterol en la sangre?.